Osteoarthritis Models

  Osteoarthritis (OA) affects 32.5 million people in the U.S. and 600 million people worldwide. By 2050, this number is projected to approach the 1 billion mark. The overall economic burden associated with OA in the U.S. is estimated at $136.8 billion annually.

There is no cure for this debilitating chronic joint disease. 

Lunatum Biotech is your preclinical CRO with a special focus on CRO osteoarthritis services offering sophisticated, established, valid, and reproducible in-vitro and in-vivo osteoarthritis models:

in-vitro:

- 2D and 3D culture of cartilage cells, synovium cells, adipose cells, bone cells, immune cells, single culture or co-culture system, using cells from various species, including human cells; 

- tissue explant culture, in-vitro simulation of a joint (mini joint), using tissue from various species 

in-vivo:

Osteoarthritis (OA) animal models (mouse, rat, rabbit, minipig, sheep):

 chemically induced OA: 

In the MIA model, OA is induced chemically through intra-articular injection of monosodium iodoacetate (MIA).

surgically induced OA:

The MMT+MCLT model involves the surgical induction of OA through procedures such as medial meniscal tear (MMT) and medial collateral ligament transection (MCLT).

In the ACLT model, OA is surgically induced through anterior cruciate ligament transection (ACLT).

The ACLT+pMMx model involves the surgical induction of OA through procedures like anterior cruciate ligament transection (ACLT) and partial medial meniscectomy (pMMx).

Evaluation:

Lunatum Biotech offers preclinical osteoarthritis research services using an array of the most widely accepted and meaningful evaluation methods: PCR, NGS, Western blotting, ELISA, histology, immunohistochemistry, x-ray, CT, MRI, IVIS, biomechanical testing, pain assessment, gait analysis and more ...